Interferon-inducible guanylate binding protein (GBP2) is associated with better prognosis in breast cancer and indicates an efficient T cell response

Breast Cancer

Volumn 21, Issue 4, 2014, Pages 491-499

  Godoy, Patricio ^a   Cadenas, Cristina ^a   Hellwig, Birte ^b   Marchan, Rosemarie ^a   Stewart, Joanna ^a   Reif, Raymond ^a   Lohr, Miriam ^b   Gehrmann, Matthias ^c   Rahnenführer, Jörg ^b   Schmidt, Markus ^d   Hengstler, Jan G ^a  

^a LEIBNIZ RESEARCH CENTRE FOR WORKING ENVIRONMENT AND HUMAN FACTORS   (Germany)

^b TU DORTMUND UNIVERSITY   (Germany)

^c BAYER AG   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Breast cancer; GBP2; Gene arrays; Inflammation

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GUANINE NUCLEOTIDE BINDING PROTEIN; INTERFERON INDUCIBLE GUANINE NUCLEOTIDE BINDING PROTEIN 2; MESSENGER RNA; PACLITAXEL; UBIQUITIN CONJUGATING ENZYME E2; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GBP2 PROTEIN, HUMAN; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PATIENT; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE INTERVAL; DRUG RESPONSE; FEMALE; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL TIME; T LYMPHOCYTE; ADJUVANT THERAPY; BREAST NEOPLASMS; COHORT ANALYSIS; DNA MICROARRAY; ENZYME IMMUNOASSAY; FOLLOW UP; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GTP-BINDING PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; T-LYMPHOCYTES; TUMOR MARKERS, BIOLOGICAL;

EID: 84904723337     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-012-0404-8     Document Type: Article

References (46)

1. Traver MK, Henry SC, Cantillana V, Oliver T, Hunn JP, Howard JC, et al. Immunity-related GTPase M (IRGM) proteins influence the localization of guanylate-binding protein 2 (GBP2) by modulating macroautophagy. J Biol Chem. 2011;286(35):30471-80.
2. Balasubramanian S, Fan M, Messmer-Blust AF, Yang CH, Trendel JA, Jeyaratnam JA, et al. The interferon-gamma-induced GTPase, mGBP-2, inhibits tumor necrosis factor alpha (TNF-alpha) induction of matrix metalloproteinase-9 (MMP-9) by inhibiting NF-kappaB and Rac protein. J Biol Chem. 2011; 286(22):20054-64.
3. Abdullah N, Balakumari M, Sau AK. Dimerization and its role in GMP formation by human guanylate binding proteins. Biophys J. 2010;99(7):2235-44.
4. Messmer-Blust AF, Balasubramanian S, Gorbacheva VY, Jeyaratnam JA, Vestal DJ. The interferon-gamma-induced murine guanylate-binding protein-2 inhibits rac activation during cell spreading on fibronectin and after platelet-derived growth factor treatment: role for phosphatidylinositol 3-kinase. Mol Biol Cell. 2010;21(14):2514-28.
5. Freeman WM, Bixler GV, Brucklacher RM, Lin CM, Patel KM, VanGuilder HD, et al. A multistep validation process of biomarkers for preclinical drug development. Pharmacogenomics J. 2010;10(5):385-95.
6. Kobayashi S, Nagano H, Marubashi S, Hama N, Eguchi TA, Takeda Y, et al. Guanylate-binding protein 2 mRNA in peripheral blood leukocytes of liver transplant recipients as a marker for acute cellular rejection. Transpl Int. 2010;23(4):390-6.
7. Guimaraes DP, Oliveira IM, de Moraes E, Paiva GR, Souza DM, Barnas C, et al. Interferon-inducible guanylate binding protein (GBP)-2: a novel p53-regulated tumor marker in esophageal squamous cell carcinomas. Int J Cancer. 2009;124(2):272-9.
8. Wei L, Fan M, Xu L, Heinrich K, Berry MW, Homayouni R, et al. Bioinformatic analysis reveals cRel as a regulator of a subset of interferon-stimulated genes. J Interferon Cytokine Res. 2008;28(9):541-51.
9. Kresse A, Konermann C, Degrandi D, Beuter-Gunia C, Wuerthner J, Pfeffer K, et al. Analyses of murine GBP homology clusters based on in silico, in vitro and in vivo studies. BMC Genomics. 2008;9:158.
10. Ma G, Huang J, Sun N, Liu X, Zhu M, Wu Z, et al. Molecular characterization of the porcine GBP1 and GBP2 genes. Mol Immunol. 2008;45(10):2797-807.
11. MacMicking JD. IFN-inducible GTPases and immunity to intracellular pathogens. Trends Immunol. 2004;25(11):601-9. (Pubitemid 39369737)
12. Vestal DJ, Buss JE, McKercher SR, Jenkins NA, Copeland NG, Kelner GS, et al. Murine GBP-2: a new IFN-gamma-induced member of the GBP family of GTPases isolated from macrophages. J Interferon Cytokine Res. 1998;18(11):977-85. (Pubitemid 28565801)
13. Gorbacheva VY, Lindner D, Sen GC, Vestal DJ. The interferon (IFN)-induced GTPase, mGBP-2. Role in IFN-gamma-induced murine fibroblast proliferation. J Biol Chem. 2002;277(8): 6080-7. (Pubitemid 34968394)
14. Cheng YS, Colonno RJ, Yin FH. Interferon induction of fibroblast proteins with guanylate binding activity. J Biol Chem. 1983;258(12):7746-50. (Pubitemid 13038014)
15. Cheng YS, Becker-Manley MF, Chow TP, Horan DC. Affinity purification of an interferon-induced human guanylate-binding protein and its characterization. J Biol Chem. 1985;260(29): 15834-9. (Pubitemid 16169360)
16. Giampieri S, Manning C, Hooper S, Jones L, Hill CS, Sahai E. Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol. 2009;11(11):1287-96.
17. Ramsauer K, Farlik M, Zupkovitz G, Seiser C, Kroger A, Hauser H, et al. Distinct modes of action applied by transcription factors STAT1 and IRF1 to initiate transcription of the IFN-gammainducible gbp2 gene. Proc Natl Acad Sci USA. 2007;104(8): 2849-54. (Pubitemid 46327968)
18. Schmidt M, Hasenclever D, Schaeffer M, Boehm D, Cotarelo C, Steiner E, et al. Prognostic effect of epithelial cell adhesion molecule overexpression in untreated node-negative breast cancer. Clin Cancer Res. 2008;14(18):5849-55.
19. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008;68(13):5405-13.
20. Schmidt M, Petry IB, Bohm D, Lebrecht A, von Torne C, Gebhard S, et al. Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer. Breast Cancer Res Treat. 2011;125(3):637-46.
21. Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, et al. A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin kappa C as a compatible prognostic marker in human solid tumors. Clin Cancer Res. 2012;18(9):2695-703.
22. Cadenas C, Franckenstein D, Schmidt M, Gehrmann M, Hermes M, Geppert B, et al. Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer. Breast Cancer Res. 2010;12(3):R44.
23. Hellwig B, Hengstler JG, Schmidt M, Gehrmann MC, Schormann W, Rahnenfuhrer J. Comparison of scores for bimodality of gene expression distributions and genome-wide evaluation of the prognostic relevance of high-scoring genes. BMC Bioinforma. 2010;11:276.
24. Lee JH, Jung C, Javadian-Elyaderani P, Schweyer S, Schutte D, Shoukier M, et al. Pathways of proliferation and antiapoptosis driven in breast cancer stem cells by stem cell protein piwil2. Cancer Res. 2010;70(11):4569-79.
25. Petry IB, Fieber E, Schmidt M, Gehrmann M, Gebhard S, Hermes M, et al. ERBB2 induces an antiapoptotic expression pattern of Bcl-2 family members in node-negative breast cancer. Clin Cancer Res. 2010;16(2):451-60.
26. Brase JC, Schmidt M, Fischbach T, Sultmann H, Bojar H, Koelbl H, et al. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin Cancer Res. 2010;16(8):2391-401.
27. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005; 365(9460):671-9. (Pubitemid 40260888)
28. Yu JX, Sieuwerts AM, Zhang Y, Martens JW, Smid M, Klijn JG, et al. Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer. BMC Cancer. 2007;7:182.
29. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res. 2007;13(11):3207-14. (Pubitemid 46944903)
30. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol. 2007;25(10):1239-46. (Pubitemid 46640570)
31. Popovici V, Chen W, Gallas BG, Hatzis C, Shi W, Samuelson FW, et al. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res. 2010;12(1):R5.
32. Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, et al. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res. 2010;16(21):5351-61.
33. Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M, et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol. 2007;8(12):1071-8. (Pubitemid 350182953)
34. Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Li Y, et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med. 2010; 16(2):214-8.
35. Iwamoto T, Bianchini G, Booser D, Qi Y, Coutant C, Shiang CY, et al. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst. 2011;103(3):264-72.
36. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008;14(16):5158-65.
37. Micke P, Basrai M, Faldum A, Bittinger F, Ronnstrand L, Blaukat A, et al. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin Cancer Res. 2003;9(1):188-94. (Pubitemid 36109732)
38. Steiner E, Pollow K, Hasenclever D, Schormann W, Hermes M, Schmidt M, et al. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer. Gynecol Oncol. 2008;108(3): 569-76.
39. Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M, et al. ErbB-3 predicts survival in ovarian cancer. J Clin Oncol. 2006;24(26):4317-23. (Pubitemid 46630790)
40. Hengstler JG, Lange J, Kett A, Dornhofer N, Meinert R, Arand M, et al. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer. Cancer Res. 1999;59(13): 3206-14. (Pubitemid 29316024)
41. Schmidt M, Hengstler JG, von Torne C, Koelbl H, Gehrmann MC. Coordinates in the universe of node-negative breast cancer revisited. Cancer Res. 2009;69(7):2695-8.
42. Schmidt M, Victor A, Bratzel D, Boehm D, Cotarelo C, Lebrecht A, et al. Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer - comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial. Ann Oncol. 2009;20(2):258-64.
43. Schmidt M, Gehrmann M, Hengstler JG, Koelbl H. New prognostic and predictive factors in breast cancer. Minerva Ginecol. 2010;62(6):599-611.
44. Shedden K, Xie XT, Chandaroy P, Chang YT, Rosania GR. Expulsion of small molecules in vesicles shed by cancer cells: association with gene expression and chemosensitivity profiles. Cancer Res. 2003;63(15):4331-7. (Pubitemid 36950999)
45. Raponi M, Zhang Y, Yu J, Chen G, Lee G, Taylor JM, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res. 2006;66(15): 7466-72. (Pubitemid 44289200)
46. Bild AH, Potti A, Nevins JR. Linking oncogenic pathways with therapeutic opportunities. Nat Rev. 2006;6(9):735-41. (Pubitemid 44304232)